[Optimal 3] A Phase Iii Trial To Evaluate The Efficacy And Safety Of Dhp107 (Liporaxel, Oral Paclitaxel) Compared To Taxol (Iv Paclitaxel) As First Line Therapy In Patients With Recurrent Or Metastatic Her2 Negative Breast Cancer (Bc) (Nct03315364).

Sung-Bae Kim,Qingyuan Zhang,Tao Sun,Jae Hong Seo,Keun Seok Lee,Tae-Yong Kim,Zhongsheng Tong,Kyong Hwa Park,Yong Wha Moon,Shusen Wang,Wei Li,Yaewon Yang,Jingfen Wang,Xian Wang,Jonggwon Choi,Ji Eun Lee,Koung Eun Yoon, Seongwuen Chung,Binghe Xu,Joohyuk Sohn

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 4|浏览50

暂无评分

摘要

TPS1106Background: Paclitaxel is a microtubule-stabilizing drug used for various cancers including breast cancer (BC) and gastric cancer (GC). DHP107 is an oral paclitaxel solution formulated with ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要